<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001729510</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, $0.0001 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>09/30/2026</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001802369</issuerCik>
        <issuerName>ADARx Pharmaceuticals, Inc.</issuerName>
        <issuerCusips>
          <issuerCusipNumber>00654F105</issuerCusipNumber>
        </issuerCusips>
        <issuerPrincipalExecutiveOfficeAddress>
          <street1 xmlns="http://www.sec.gov/edgar/common">5871 Oberlin Drive, Suite 200</street1>
          <city xmlns="http://www.sec.gov/edgar/common">San Diego</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">CA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">92121</zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(d)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Zhen Li</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>4939795.00</soleVotingPower>
        <sharedVotingPower>5911763.00</sharedVotingPower>
        <soleDispositivePower>4939795.00</soleDispositivePower>
        <sharedDispositivePower>5911763.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>10851558.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.7</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>(1) Amount reported in Row (9) consists of (i) 4,939,795 shares of Common Stock (as defined herein) subject to options held by the Reporting Person that are exercisable within 60 days of September 30, 2026, (ii) 5,861,199 shares of Common Stock held by the Titanium Boulder Irrevocable Trust dated July 11, 2020 (the "Titanium Trust"), for which the Reporting Person and her spouse serve as trustees, and (iii) 50,564 shares of Common Stock subject to options held by the Reporting Person's spouse that are exercisable within 60 days of September 30, 2026.  The Reporting Person and her spouse, as trustees of the Titanium Trust, share voting and dispositive power with respect to the securities held by the Titanium Trust. The Reporting Person disclaims beneficial ownership of the shares of Common Stock subject to options held by the Reporting Person's spouse.

(2) Percent of class represented by amount in Row (11) is based on the sum of (i) 107,255,963 shares of Common Stock issued and outstanding as of September 30, 2026, (ii) 4,939,795 shares of Common Stock issuable upon exercise of options held by the Reporting Person within 60 days of September 30, 2026, and (iii) 50,564 shares of Common Stock issuable upon exercise of options held by the Reporting Person's spouse within 60 days of September 30, 2026, which shares have been added to the total shares of Common Stock outstanding pursuant to Rule 13d-3(d)(1)(i) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>ADARx Pharmaceuticals, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>5871 Oberlin Drive, Suite 200, San Diego, CA 92121</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>This statement is being filed by Zhen Li (the "Reporting Person").</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>The principal business address of the Reporting Person is c/o ADARx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121.</principalBusinessOfficeOrResidenceAddress>
        <citizenship>The Reporting Person is a citizen of the United States.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>As of September 30, 2026, the Reporting Person may be deemed the beneficial owner of 10,851,558 shares of Common Stock, $0.0001 par value per share (the "Common Stock").

This amount consists of (i) 4,939,795 shares of Common Stock subject to options held by the Reporting Person that are exercisable within 60 days of September 30, 2026, (ii) 5,861,199 shares of Common Stock held by the Titanium Trust, for which the Reporting Person and her spouse serve as trustees, and (iii) 50,564 shares of Common Stock subject to options held by the Reporting Person's spouse that are exercisable within 60 days of September 30, 2026.

The Reporting Person and her spouse, as trustees of the Titanium Trust, share voting and dispositive power with respect to the securities held by the Titanium Trust. The Reporting Person disclaims beneficial ownership of the shares of Common Stock subject to options held by the Reporting Person's spouse.</amountBeneficiallyOwned>
        <classPercent>As of September 30, 2026, the Reporting Person may be deemed to beneficially own approximately 9.7% of the shares of Common Stock outstanding.

The foregoing percentage is based on the sum of (i) 107,255,963 shares of Common Stock issued and outstanding as of September 30, 2026, (ii) 4,939,795 shares of Common Stock issuable upon exercise of options held by the Reporting Person within 60 days of September 30, 2026, and (iii) 50,564 shares of Common Stock issuable upon exercise of options held by the Reporting Person's spouse within 60 days of September 30, 2026, which shares have been added to the total shares of Common Stock outstanding pursuant to Rule 13d-3(d)(1)(i) under the Exchange Act.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>4,939,795.00</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>5,911,763.00</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>4,939,795.00</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>5,911,763.00</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>N</notApplicableFlag>
        <ownershipMoreThan5PercentOnBehalfOfAnotherPerson>The Titanium Trust has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the shares of Common Stock outstanding.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>Y</notApplicableFlag>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Zhen Li</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Zhen Li</signature>
        <title>Zhen Li</title>
        <date>11/13/2026</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
